{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:31Z","timestamp":1794045811296,"version":"4.8.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"\n Importance<\/jats:title>\n Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To test whether the risk of hospitalization due to alcohol use disorder (AUD) is decreased during the use of GLP-1 agonists compared with periods of nonuse for the same individual.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was an observational study conducted nationwide in Sweden using data from January 2006 to December 2023. The population-based cohort was identified from registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. Participants were all residents aged 16 to 64 years who had a diagnosis of AUD.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n The primary exposure was use of individual GLP-1 agonists (compared with nonuse of GLP-1 agonists), and the secondary exposure was medications with indication for AUD.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was AUD hospitalization analyzed in a Cox regression within-individual model. Secondary outcomes were any substance use disorder (SUD)\u2013related hospitalization, somatic hospitalization, and suicide attempt.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 227\u202f866 individuals with AUD; 144\u202f714 (63.5%) were male and 83\u202f154 (36.5%) were female, with a mean (SD) age of 40.0 (15.7) years. Median (IQR) follow-up time was 8.8 (4.0-13.3) years. A total of 133\u202f210 individuals (58.5%) experienced AUD hospitalization. Semaglutide (4321 users) was associated with the lowest risk (AUD: adjusted hazard ratio [aHR], 0.64; 95% CI, 0.50-0.83; any SUD: aHR, 0.68; 95% CI, 0.54-0.85) and use of liraglutide (2509 users) with the second lowest risk (AUD: aHR, 0.72; 95% CI, 0.57-0.92; any SUD: aHR, 0.78; 95% CI, 0.64-0.97) of both AUD and SUD hospitalization. Use of any AUD medication was associated with a modestly decreased risk (aHR, 0.98; 95% CI, 0.96-1.00). Semaglutide (aHR, 0.78; 95% CI, 0.68-0.90) and liraglutide (aHR, 0.79; 95% CI, 0.69-0.91) use were also associated with decreased risk of somatic hospitalizations but not associated with suicide attempts (semaglutide: aHR, 0.55; 95% CI, 0.23-1.30; liraglutide: aHR, 1.08; 95% CI, 0.55-2.15).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with AUD and comorbid obesity\/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2024.3599","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:38:44Z","timestamp":1731497924000},"page":"94","source":"Crossref","is-referenced-by-count":150,"title":["Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder"],"prefix":"10.1001","volume":"82","author":[{"given":"Markku","family":"L\u00e4hteenvuo","sequence":"first","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Solismaa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland"},{"name":"Department of Psychiatry, The Pirkanmaa Wellbeing Services County, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellenor","family":"Mittendorfer-Rutz","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[{"name":"Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden"},{"name":"School of Pharmacy, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ybr240008r2","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/add.15384","article-title":"Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125?556 patients.","volume":"116","author":"Heikkinen","year":"2021","journal-title":"Addiction"},{"issue":"12","key":"ybr240008r3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S2215-0366(19)30213-5","article-title":"Prevention, screening, and treatment for heavy drinking and alcohol use disorder.","volume":"6","author":"Knox","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"ybr240008r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats.","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"issue":"1","key":"ybr240008r5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00213-019-05374-1","article-title":"Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.","volume":"237","author":"Thomsen","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"ybr240008r6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series.","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"ybr240008r7","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence.","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl Psychiatry"},{"issue":"5","key":"ybr240008r8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events: a nationwide register-based cohort and self-controlled case series study.","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"ybr240008r9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12911-015-0140-z","article-title":"From prescription drug purchases to drug use periods: a second generation method (PRE2DUP).","volume":"15","author":"Tanskanen","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"ybr240008r10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CLEP.S116160","article-title":"Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons.","volume":"8","author":"Taipale","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"8","key":"ybr240008r12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"issue":"12","key":"ybr240008r13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission.","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"4","key":"ybr240008r14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"ybr240008r11","doi-asserted-by":"crossref","DOI":"10.4135\/9781412993869","volume-title":"Fixed Effects Regression Models","author":"Allison","year":"2009"},{"key":"ybr240008r1","unstructured":"World Health Organization. Global status report on alcohol and health 2018.Accessed May 20, 2024. https:\/\/apps.who.int\/iris\/handle\/10665\/274603"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2825650\/jamapsychiatry_lhteenvuo_2024_br_240008_1735586225.43864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T11:01:32Z","timestamp":1735815692000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2825650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3599","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}